Research progress of HIV broadly neutralizing antibodies
Author:
Affiliation:

Comparative Medicine Center, Peking Union Medical College (PUMC). Institute of Medical Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS). Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious. NHC Key Laboratory of Human Disease Comparative Medicine, Beijing 100021, China

Clc Number:

R-33

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    The HIV virus is widespread worldwide, leading to the serious and infectious acquired immunodeficiency syndrome (AIDS), and serious impacts on human life, health and social development. Although highly active antiretroviral therapy can inhibit HIV virus replication, it is not able to eliminate virus from the body. Preventive vaccines are an important tool against HIV, but because the virus has genetic diversity and strong variability, such vaccines must be able to induce broadly neutralizing antibodies ( bNAbs) that broadly and effectively neutralize HIV strains. Research targeting the induction and generation of bNAbs for the prevention of HIV has many challenges, and it is necessary to further strengthen the scientific and technological efforts in related research directions. This review summarizes the latest progress in HIV bNAbs, including biological characteristics, production mechanisms, induction strategies and other aspects, with the goal to provide basic information and possible directions for subsequent research.

    Reference
    Related
    Cited by
Get Citation
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:December 08,2020
  • Revised:
  • Adopted:
  • Online: November 29,2021
  • Published: